SCHEMBL3548566

SCHEMBL3548566

Cc1onc(-c2ccccc2)c1C(=O)N1CCC(C(N)=O)CC1

nearest known ligand 0.73

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.73
KMT2A Q03164 2/20 0.72
SMN1; SMN2 Q16637 3/20 0.70
HTT P42858 1/20 0.70
TSHR P16473 2/20 0.69
USP2 O75604 1/20 0.69
NPSR1 Q6W5P4 1/20 0.66
LMNA P02545 4/20 0.63
ALDH1A1 P00352 2/20 0.62
NPC1 O15118 1/20 0.59
GAA P10253 2/20 0.59
MEN1 O00255 1/20 0.59
TP53 P04637 1/20 0.58
HCRTR1 O43613 1/20 0.57
HCRTR2 O43614 1/20 0.57
MAPK1 P28482 1/20 0.57
L3MBTL1 Q9Y468 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3544581 0.84 KDM4E (1.00) KDM4EKMT2ASMN1; SMN2HTTTSHR
SCHEMBL3539489 0.84 KMT2A (1.00) KDM4EKMT2ASMN1; SMN2HTTTSHR
SCHEMBL3553134 0.84 SMN1; SMN2 (0.97) KDM4EKMT2ASMN1; SMN2HTTTSHR
SCHEMBL4238481 0.84 KMT2A (0.68) KDM4EKMT2ASMN1; SMN2HTTTSHR
SCHEMBL3661239 0.84 KMT2A (0.68) KDM4EKMT2ASMN1; SMN2HTTTSHR
SCHEMBL3543294 0.83 KDM4E (0.66) KDM4EKMT2ASMN1; SMN2HTTTSHR
SCHEMBL3553965 0.82 TSHR (1.00) KDM4EKMT2ASMN1; SMN2HTTTSHR
SCHEMBL3546099 0.81 KMT2A (0.79) KDM4EKMT2ASMN1; SMN2HTTTSHR
SCHEMBL3543233 0.81 KMT2A (0.70) KDM4EKMT2ASMN1; SMN2HTTTSHR
SCHEMBL3543194 0.80 KMT2A (0.65) KDM4EKMT2ASMN1; SMN2HTTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7666888-B2 Substituted azole aromatic heterocycles as inhibitors of 11β-HSD-1 AMGEN INC. (US) 2010-02-23 US disclosed
US-7666888-B2 Substituted azole aromatic heterocycles as inhibitors of 11β-HSD-1 AMGEN INC. (US) 2010-02-23 US disclosed
US-7666888-B2 Substituted azole aromatic heterocycles as inhibitors of 11β-HSD-1 AMGEN INC. (US) 2010-02-23 US disclosed
EP-2051977-A2 SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLbeta-HSD-1 Amgen Inc. (US) 2009-04-29 EP disclosed
WO-2008011453-A2 SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLβ-HSD-1 AMGEN INC. (US) 2008-01-24 WO disclosed
WO-2008011453-A2 SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLβ-HSD-1 AMGEN INC. (US) 2008-01-24 WO disclosed
US-20080021022-A1 SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF 11BETA-HSD-1 AMGEN INC. 2008-01-24 US disclosed
US-20080021022-A1 SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF 11BETA-HSD-1 AMGEN INC. 2008-01-24 US disclosed
US-20080021022-A1 SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF 11BETA-HSD-1 AMGEN INC. 2008-01-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080021022-A1 SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF 11BETA-HSD-1 HSD17B1, HSD11B1, HSD17B11 KDM4E 702/4885KMT2A 2389/4885SMN1; SMN2 3710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.